87 related articles for article (PubMed ID: 20403050)
1. Aggressive progression of breast cancer with microscopic pulmonary emboli possessing a stem cell-like phenotype independent of its origin.
Kawasaki H; Ogura H; Arai Y; Baba S; Kosugi I; Tsutsui Y; Iwashita T
Pathol Int; 2010 Mar; 60(3):228-34. PubMed ID: 20403050
[TBL] [Abstract][Full Text] [Related]
2. [Pulmonary tumor embolism: Report of two cases].
Chertcoff FJ; Emery NC; Villagomez R; Veltri MA; Venditti J; Young P; Ubaldini J
Rev Med Chil; 2009 Dec; 137(12):1613-6. PubMed ID: 20361139
[TBL] [Abstract][Full Text] [Related]
3. The differential diagnosis of dyspnea in a woman with metastatic breast cancer--consideration beyond pulmonary embolism.
Dizon DS; Beheshti J; McDonough K; Gass J
Breast J; 2008; 14(1):90-1. PubMed ID: 18186870
[TBL] [Abstract][Full Text] [Related]
4. Association of breast cancer stem cells identified by aldehyde dehydrogenase 1 expression with resistance to sequential Paclitaxel and epirubicin-based chemotherapy for breast cancers.
Tanei T; Morimoto K; Shimazu K; Kim SJ; Tanji Y; Taguchi T; Tamaki Y; Noguchi S
Clin Cancer Res; 2009 Jun; 15(12):4234-41. PubMed ID: 19509181
[TBL] [Abstract][Full Text] [Related]
5. [Cancer patient with dyspnoe--remember the possibility of pulmonary tumor microembolism].
Kiljunen M; Rinta-Kiikka I; Bärlund M; Lagerstedt A
Duodecim; 2010; 126(18):2147-52. PubMed ID: 21072962
[TBL] [Abstract][Full Text] [Related]
6. A novel mouse model of human breast cancer stem-like cells with high CD44+CD24-/lower phenotype metastasis to human bone.
Ling LJ; Wang S; Liu XA; Shen EC; Ding Q; Lu C; Xu J; Cao QH; Zhu HQ; Wang F
Chin Med J (Engl); 2008 Oct; 121(20):1980-6. PubMed ID: 19080260
[TBL] [Abstract][Full Text] [Related]
7. Circulating tumor cells with a putative stem cell phenotype in peripheral blood of patients with breast cancer.
Theodoropoulos PA; Polioudaki H; Agelaki S; Kallergi G; Saridaki Z; Mavroudis D; Georgoulias V
Cancer Lett; 2010 Feb; 288(1):99-106. PubMed ID: 19619935
[TBL] [Abstract][Full Text] [Related]
8. Most early disseminated cancer cells detected in bone marrow of breast cancer patients have a putative breast cancer stem cell phenotype.
Balic M; Lin H; Young L; Hawes D; Giuliano A; McNamara G; Datar RH; Cote RJ
Clin Cancer Res; 2006 Oct; 12(19):5615-21. PubMed ID: 17020963
[TBL] [Abstract][Full Text] [Related]
9. Characterizing the HER2/neu status and metastatic potential of breast cancer stem/progenitor cells.
Pommier SJ; Quan GG; Christante D; Muller P; Newell AE; Olson SB; Diggs B; Muldoon L; Neuwelt E; Pommier RF
Ann Surg Oncol; 2010 Feb; 17(2):613-23. PubMed ID: 19838757
[TBL] [Abstract][Full Text] [Related]
10. The clinicopathologic and prognostic significance of CD44+/CD24(-/low) and CD44-/CD24+ tumor cells in invasive breast carcinomas.
Mylona E; Giannopoulou I; Fasomytakis E; Nomikos A; Magkou C; Bakarakos P; Nakopoulou L
Hum Pathol; 2008 Jul; 39(7):1096-102. PubMed ID: 18495204
[TBL] [Abstract][Full Text] [Related]
11. [The cancer stem cell: the breast cancer driver].
Ginestier C; Korkaya H; Dontu G; Birnbaum D; Wicha MS; Charafe-Jauffret E
Med Sci (Paris); 2007 Dec; 23(12):1133-9. PubMed ID: 18154716
[TBL] [Abstract][Full Text] [Related]
12. Prevalence of CD44+/CD24-/low cells in breast cancer may not be associated with clinical outcome but may favor distant metastasis.
Abraham BK; Fritz P; McClellan M; Hauptvogel P; Athelogou M; Brauch H
Clin Cancer Res; 2005 Feb; 11(3):1154-9. PubMed ID: 15709183
[TBL] [Abstract][Full Text] [Related]
13. Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy.
Li X; Lewis MT; Huang J; Gutierrez C; Osborne CK; Wu MF; Hilsenbeck SG; Pavlick A; Zhang X; Chamness GC; Wong H; Rosen J; Chang JC
J Natl Cancer Inst; 2008 May; 100(9):672-9. PubMed ID: 18445819
[TBL] [Abstract][Full Text] [Related]
14. Cancer presenting as fatal pulmonary tumour embolism.
Deeren D; Verbeken E; Vanderschueren S; Wilmer A; Bobbaers H; Meersseman W
Acta Clin Belg; 2006; 61(1):30-4. PubMed ID: 16673614
[TBL] [Abstract][Full Text] [Related]
15. Prognostic significance of molecular classification of breast invasive ductal carcinoma.
Muñoz M; Fernández-Aceñero MJ; Martín S; Schneider J
Arch Gynecol Obstet; 2009 Jul; 280(1):43-8. PubMed ID: 19082617
[TBL] [Abstract][Full Text] [Related]
16. Increased expression of osteopontin in patients with triple-negative breast cancer.
Wang X; Chao L; Ma G; Chen L; Tian B; Zang Y; Sun J
Eur J Clin Invest; 2008 Jun; 38(6):438-46. PubMed ID: 18452545
[TBL] [Abstract][Full Text] [Related]
17. Recent translational research: stem cells as the roots of breast cancer.
Chang CC
Breast Cancer Res; 2006; 8(1):103. PubMed ID: 16524453
[TBL] [Abstract][Full Text] [Related]
18. Her-2/neu expression in node-negative breast cancer: direct tissue quantitation by computerized image analysis and association of overexpression with increased risk of recurrent disease.
Press MF; Pike MC; Chazin VR; Hung G; Udove JA; Markowicz M; Danyluk J; Godolphin W; Sliwkowski M; Akita R
Cancer Res; 1993 Oct; 53(20):4960-70. PubMed ID: 8104689
[TBL] [Abstract][Full Text] [Related]
19. Clinical, histopathologic, and immunohistochemical features of microglandular adenosis and transition into in situ and invasive carcinoma.
Khalifeh IM; Albarracin C; Diaz LK; Symmans FW; Edgerton ME; Hwang RF; Sneige N
Am J Surg Pathol; 2008 Apr; 32(4):544-52. PubMed ID: 18300793
[TBL] [Abstract][Full Text] [Related]
20. Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization.
Basu S; Chen W; Tchou J; Mavi A; Cermik T; Czerniecki B; Schnall M; Alavi A
Cancer; 2008 Mar; 112(5):995-1000. PubMed ID: 18098228
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
